JAZZ Earnings
Latest Revenue1.2B
Latest Net Income192.8M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $3.05 | 1.2B | 192.8M | +15.5% | +126.0% |
| Q1 2026 | $4.73 | 1.1B | 293.1M | +19.1% | +411.2% |
| Q4 2025 | $3.33 | 1.2B | 203.5M | +10.1% | +5.4% |
| Q3 2025 | $4.14 | 1.1B | 251.4M | +6.7% | +18.3% |
| Q2 2025 | -$11.74 | 1.0B | -718500000 | +2.1% | -538.1% |
| Q1 2025 | -$1.52 | 897.8M | -92500000 | -0.5% | -560.9% |
| Q4 2024 | $3.16 | 1.1B | 191.1M | +7.5% | +110.7% |
| Q3 2024 | $3.50 | 1.1B | 215.1M | +8.5% | +50.2% |
| Q2 2024 | $2.68 | 1.0B | 168.6M | — | — |
| Q1 2024 | -$0.23 | 902.0M | -14618000 | — | — |
| Q4 2023 | $1.50 | 1.0B | 94.2M | — | — |
| Q3 2023 | $2.33 | 972.1M | 146.8M | — | — |
Jazz Pharmaceuticals (JAZZ) — Earnings